Karsten Weber
YOU?
Author Swipe
View article: Recording and understanding multi- and intermodal mobility - a review
Recording and understanding multi- and intermodal mobility - a review Open
The transition to sustainable mobility requires detailed knowledge of actual mobility behavior. Recording mobility behavior through conventional, aggregated, or retrospective survey methods (e.g., counting stations, travel diaries) may yie…
View article: Public images of artificial intelligence: an overview
Public images of artificial intelligence: an overview Open
Artificial intelligence (AI) is not only a ubiquitous topic in scholarly debates but in recent years has also received increased media and political attention. Discussions, initially strongly influenced by autonomous vehicles but currently…
View article: Sharing health data for research purposes: results of a population survey in Germany
Sharing health data for research purposes: results of a population survey in Germany Open
We present evidence from a random sample of the German population. The results indicate widespread support among the population for providing access to health data for research purposes. Similar to findings in other countries, the willingn…
View article: Acceptance and Usage of AI Applications in Health-Focused NGOs
Acceptance and Usage of AI Applications in Health-Focused NGOs Open
Background: AI applications promise to be a valuable tool for health-focused NGOs. While often operating with limited resources, these organizations recognize the potential of AI to streamline processes and support workflows through automa…
View article: AI for decision support: What are possible futures, social impacts, regulatory options, ethical conundrums and agency constellations?
AI for decision support: What are possible futures, social impacts, regulatory options, ethical conundrums and agency constellations? Open
Although artificial intelligence (AI) and automated decision-making systems have been around for some time, they have only recently gained in importance as they are now actually being used and are no longer just the subject of research. AI…
View article: AI‑based decision support systems and society: An opening statement
AI‑based decision support systems and society: An opening statement Open
Although artificial intelligence (AI) and automated decision-making systems have been around for some time, they have only recently gained in importance as they are now actually being used and are no longer just the subject of research. AI…
View article: Analyzing factors determining vaccination willingness against COVID-19 in Germany 2020
Analyzing factors determining vaccination willingness against COVID-19 in Germany 2020 Open
The study is based on a German single-topic population survey on vaccination willingness against COVID-19 (VWC) by the authors (2020, n = 2014). The single-topic survey allowed us to test several competing explanations for VWC, as discusse…
View article: Data from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Data from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Purpose:We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer.Experimental Design:Targeted mRNA sequencing of 2,559 transcripts was performe…
View article: Supplementary Table S3: Hazard ratios (HR) and confidence intervals (CI) for disease-free survival (DFS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Table S3: Hazard ratios (HR) and confidence intervals (CI) for disease-free survival (DFS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Changes of CTC numbers in the total study cohort or in any of the different subgroups were not related to DFS.
View article: Supplementary Table S1: Circulating tumor cells (CTCs) and patient characteristics before and after neoadjuvant therapy (NT) from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Table S1: Circulating tumor cells (CTCs) and patient characteristics before and after neoadjuvant therapy (NT) from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Detection of CTCs associated with patient and tumor characteristics for both time points is listed. There was no significant correlation of {greater than or equal to}1CTC or {greater than or equal to}2CTCs to any of these parameters.
View article: Data from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Data from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Open
Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chem…
View article: Supplementary Figures from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Supplementary Figures from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial Open
Supplementary Figures
View article: Supplementary Data revised from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Supplementary Data revised from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial Open
Supplementary materials and tables
View article: Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Differentially expressed genes according to treatment response
View article: Supplementary Figure S1 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Figure S1 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Supplementary Figure S1: Kaplan Meier plots for disease-free (DFS) and overall survival (OS) according CTC detection after NT. (A, B) DFS, analysis of the whole patient cohort at CTC cut-offs {greater than or equal to}1 (A) and {greater th…
View article: Supplementary Figure S2 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Figure S2 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Supplementary Figure S2: Kaplan Meier plots by pathologic complete response (pCR) and CTCs detected after NT. (A, B) DFS, analysis of the whole patient cohort at cut-off {greater than or equal to}1 (A) CTC/7.5 mL and {greater than or equal…
View article: Figure S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Figure S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Pre-treatment biopsy samples were available for all N = 174 patients. Of those, N = 162 could be successfully profiled by targeted RNA sequencing.
View article: Online-Only Tables: 1 and Online-Only Figures: 2 from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Online-Only Tables: 1 and Online-Only Figures: 2 from Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Open
Supplementary Table 1: Multivariate analysis of the continuous mEPclin and CPS-EG scores including Ki67 status according to DFS Supplementary Figures
View article: Figure S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Figure S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Pre-treatment biopsy samples were available for all N = 174 patients. Of those, N = 162 could be successfully profiled by targeted RNA sequencing.
View article: Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Patients were randomized to receive one injection durvalumab 0.75 g i.v. or placebo two weeks prior to start of chemotherapy (window trial). This was followed by nab-paclitaxel 125 mg/m2 weekly for 12 weeks with durvalumab 1.5 g i.v. or pl…
View article: Supplementary Table S3: Hazard ratios (HR) and confidence intervals (CI) for disease-free survival (DFS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Table S3: Hazard ratios (HR) and confidence intervals (CI) for disease-free survival (DFS) using the two CTC variables and absolute CTC numbers before therapy from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Changes of CTC numbers in the total study cohort or in any of the different subgroups were not related to DFS.
View article: Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Differentially expressed genes according to treatment response
View article: Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Patients were randomized to receive one injection durvalumab 0.75 g i.v. or placebo two weeks prior to start of chemotherapy (window trial). This was followed by nab-paclitaxel 125 mg/m2 weekly for 12 weeks with durvalumab 1.5 g i.v. or pl…
View article: Supplementary Table S2: Characteristics of the 133 patients with CTC measurements at both time points from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Table S2: Characteristics of the 133 patients with CTC measurements at both time points from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Detection of CTCs associated with patient and tumor characteristics for both time points in patients with measurements at both time points is listed. There was no significant correlation of {greater than or equal to}1CTC or {greater than o…
View article: Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Bivariate logistic regression models for the immune- and proliferation-associated gene signatures
View article: Supplementary Table S2: Characteristics of the 133 patients with CTC measurements at both time points from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Table S2: Characteristics of the 133 patients with CTC measurements at both time points from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Detection of CTCs associated with patient and tumor characteristics for both time points in patients with measurements at both time points is listed. There was no significant correlation of {greater than or equal to}1CTC or {greater than o…
View article: Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Table S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer Open
Bivariate logistic regression models for the immune- and proliferation-associated gene signatures
View article: Data from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Data from Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial Open
Purpose:Next-generation sequencing (NGS) can be used for comprehensive investigation of molecular events in breast cancer. We evaluated the relevance of genomic alterations for response to neoadjuvant chemotherapy (NACT) in the GeparSepto …
View article: Supplementary Figure S3 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Supplementary Figure S3 from Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial Open
Supplementary Figure S3: Kaplan Meier plots for disease-free (DFS) and overall survival (OS) according to CTC detection after NT. (A, B) DFS, analysis of patients with HER2-positive tumors (A) and of patients with triple negative tumors (B…